We're saying a big thank you for all of our users that have been in touch and participated in our usability studies. There is still time if you would like to be involved, we'd love to hear your feedback on our pre-release sample download file.
We are excited to announce our recent commercial distribution partnership with Qiagen GmbH. This enables us to protect the future of COSMIC, and continue sustaining and maintaining our valuable resource.
Discover what COSMIC has to offer in our downloadable introductory guide to COSMIC.
We have recently launched The Cancer Mutation Census to much acclaim and success! But at COSMIC we never stop! Now we are working on our next product, Mutation Actionability in Precision Oncology!
Not only have we expertly curated 2 new genes, updated 4 existing expertly curated genes curated new drug resistance data, we have also made changes to our download files in response to user feedback. Find out more before exploring the v92 release.
We have been working on an exciting new product - The Cancer Mutation Census (CMC). Discover the CMC now!
We’re busy working hard despite lockdown and we are super proud of the team pulling this all together! The v92 release is just a few weeks away!
This post signals the first of some very exciting new developments for COSMIC Mutational Signatures. Our main focus for this release has been to make a series of design updates to adopt the COSMIC branding, plus a small data update for the signatures.
We have been working on an exciting new product - The Cancer Mutation Census (CMC). We are often asked which are the mutations that matter the most, the CMC will help to answer this question! The CMC allows for the prioritisation of somatic mutations that introduce biologically relevant changes to protein function, and participate in the development of cancer.
The CMC integrates all coding somatic mutations collected by COSMIC with biological and biochemical information from multiple sources, combining data obtained from manual curation and computational analyses.